# OnCo record armor3-sv (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/armor3-sv/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "armor3-sv", "NCT02438007" ;
  schema:name "ARMOR3-SV"@en ;
  schema:alternateName "ARMOR3-SV"@en, "galeterone against enzalutamide in AR-V7 positive disease"@en ;
  schema:description "The only trial ever to pick men for prostate cancer treatment by a splice variant of the androgen receptor. It could not recruit, because the men who qualified were too ill to stay in it."@en ;
  schema:url <https://onco.cc/trials/armor3-sv/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02438007>, <https://doi.org/10.1016/j.eururo.2019.08.034> ;
  onco:status "negative" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-mcrpc/> ;
  onco:targets <https://onco.cc/targets/androgen-receptor/>, <https://onco.cc/targets/cyp17a1/> ;
  onco:drugs <https://onco.cc/drugs/galeterone/>, <https://onco.cc/drugs/enzalutamide/> ;
  onco:terms <https://onco.cc/terms/ar-v7/>, <https://onco.cc/terms/arpi/>, <https://onco.cc/terms/castration-resistance/>, <https://onco.cc/terms/psa50/> ;
  onco:trials <https://onco.cc/trials/affirm/>, <https://onco.cc/trials/prevail/> .